The GlaxoSmithKline and Celgene-backed immunotherapy developer has floated in the middle of its range on the Nasdaq Global Market.
Lyell Immunopharma, a US-based immunotherapy developer which counts pharmaceutical firms GlaxoSmithKline (GSK) and Celgene as investors, raised $425m in its initial public offering yesterday.
The company issued 25 million shares on the Nasdaq Global Market at a price of $17 each, the mid-point of the offering’s $16 to $18 range. Its shares closed at $16.89 at the end of the day.
Founded in 2018, Lyell is developing cancer immunotherapies that reprogram T-cells, an integral component of the immune system,…
